As bstract. We have characterized Factor VIIIcoagulant protein, present in normal human plasma, that reacts with a specific human '251-labeled anti-human VIII:C antigen Fab antibody fragment. Two major Factor VIII coagulant antigen populations were present. The first, -85% of the total antigen, was bound to von Willebrand factor and when tested in a standard one-stage assay had Factor VIII coagulant activity. The second antigenic population, eluting near fibrinogen when plasma was gel filtered, was not bound to von Willebrand protein, did not have Factor VIII coagulant activity unless activated, but did block anti-VIII:C Fab neutralization of clotting activity. The two antigenic populations were separable by cryoprecipitation and agarose gel electrophoresis.
Introduction
Factor VIII:C (VIII:C)' (antihemophilic factor) plays a central role in the intrinsic blood coagulation pathway, acting as a cofactor in the reaction between Factors' IX and X. Most Factor VIII coagulant protein, under normal physiological conditions, is associated with (1, 2) but distinct from von Willebrand factor (vWF), a high molecular weight multimeric protein necessary for optimal binding of platelets to the subendothelium (3). Despite the importance ofFactor VIII in hemostasis, little is known about the structure of the protein in plasma. Difficulties in its purification caused by low plasma concentration (4) and extreme susceptibility to proteolysis (5) (6) (7) by thrombin and other enzymes have hampered its characterization.
One approach to studying Factor VIII coagulant protein with a minimum of purification is as an antigen (VIII:CAg), through the use of '25I-labeled anti-VIII:C Fab ('25I-Fab) (8, 9) . This reagent, obtained from the plasma ofa multiply transfused hemophilic patient with a high titer anti-VIII:C antibody, was specific for VIII:C-related protein, as measured by its ability to inhibit VIII:C activity and its nonreactivity with plasma from patients with severe hemophilia. '251I-Fab, when incubated with normal plasma, formed stable 1:1 stoichiometric complexes with VIII:CAg, which are resistant to urea-sodium dodecyl sulfate (SDS) denaturation at 370C. This urea-SDS treatment was sufficient, however, to dissociate VIII:CAg from vWF. The elec trophoretic mobility of 1251-Fab-VIII:CAg complexes on SDSpolyacrylamide-agarose gels (PAAGE) was used to calculate the apparent free molecular weight of VIII:CAg.
70-80% of VIII:CAg in whole plasma, when examined by SDS-PAAGE, had a molecular weight of 2.4 X 105. The remaining VIII:CAg was distributed among at least five VIII:CAg bands ranging from 0.85 X 10 to 2.6 X 10 mol wt (8) . The epitope site remained intact after thrombin proteolysis, yielding VIII:CAg forms of I and 0.8 X 10 mol wt.
In contrast to this result with urea-SDS, two major VIII:CAg populations are present when normal plasma, incubated with 1251-Fab, is gel filtered over agarose under nondenaturing conditions (9) . The first VIII:CAg peak is in the void volume (V0) fraction along with VIII:C coagulant activity and vWF. The second antigenic fraction is near the fibrinogen peak in a region without VIII:C activity. Considering the susceptibility of VIII:CAg to proteolysis, this second antigen peak could be composed of inactivated VIII:CAg fragments. Alternatively, since VIII:C activity can be dissociated from vWF in the presence of high ionic strength buffers (2, 10) , indicating association by noncovalent bonds, the second antigenic peak might contain VIII:C protein in equilibrium with that bound to vWF.
To characterize further these two antigenic populations obtained under nondenaturing conditions, we have determined their apparent molecular weight by the immunological SDS-PAAGE procedure. We have also examined the molecular weight changes in both populations after thrombin treatment, the association of antigenic fragments with vWF, and the correlation of antigenic forms with VIII:C activity.
Methods
Plasma preparation. Venous blood (9 vol) collected by a two-syringe technique, was anticoagulated with 3.8% sodium citrate, 90 National Institutes ofHealth (NIH) U/ml hirudin (Sigma Chemical Co., St. Louis, MO) , and 100 kallikrein inhibitor units (KIU)/ml Trasylol (Mobay Chemical Corp., FBA Pharmaceuticals, New York) (I vol). Plateletpoor plasma was separated by centrifuging twice at 4,000 g for 3 min (220C). Plasma samples either were used immediately or stored at -70°C for subsequent analysis. Pooled normal plasma from 14 individuals was prepared in citrate without added inhibitors.
Assays ofFactor VIII-related activities. VIII:C activity was measured by one-stage activated partial thromboplastin time (I 1) by using hemophilia A plasma as substrate (VIII:C < 1%). 1 U of VIII:C activity is the amount present in 1 ml of plasma. The coagulant assay can detect VIII:C < 0.01 U/ml. vWF antigen (Factor VIII-related antigen, VIII:RAg) was quantified by solid-phase immunoradiometric assay (12) with 1251_ labeled and unlabeled rabbit anti-human vWF (Dako Antibodies, Accurate Chemical and Scientific Corp., Westbury, NY). The assay can detect vWF antigen at levels _0.0002 U/ml, where 1 U is equivalent to that present in 1 ml of plasma.
125I-Fab, prepared by a previously described method (13) The concentration ofhuman anti-VIII:C Fab was adjusted with VBS so that a 1:1 mixture of antibody solution and diluted normal plasma (1 vol plasma in 9 vol VBS) produced, after incubation for 2 h at 370C, a 50% reduction in VIII:C activity compared with incubation of plasma with VBS alone. Before reaction with normal plasma, 1 vol of human anti-VIII:C Fab was incubated for 2 h at 370C with 1 vol either of VBS or concentrated V5 VIII:CAg (0.1 U/ml VIII:CAg, dialyzed against VBS to remove excess NaCI). Shortened clotting times (and increased VIII:C), which approached those obtained when plasma was incubated with VBS alone, indicated that V1 VIII:CAg bound to anti-VIII:C Fab and blocked the inhibition of plasma VIII:C by anti-VIII:C Fab. In control experiments, Vi VIII:CAg alone was added to normal plasma 2 h before, or simultaneously with, the initiation of clotting by calcium. Anti-VIII:C Fab was also mixed with plasma just before calcium addition.
Electrophoresis on 0.3/2% agarose gels. Agarose (SeaKem HGT, FMC Corp., Marine Colloids Division, Rockland, ME) (2%) slab gels, 1.5 X 60 X 180 mm, were poured in 0.081 M Tris-0.024 M Tricine running buffer, pH 8.6. 0.3% agarose gels, 1.5 X 30 X 180 mm, were poured adjacent to the 2% gel with a well-forming comb (Bio-Rad Laboratories) and placed 1.5 cm from the 2% gel.
Sample aliquots (30 g1) were incubated with 33 l '251I-Fab solution (at least 2,000 cpm) containing proteolytic inhibitors and PEG for 1.5 h at 37°C, and then for 0.5 h at 0°C. After rewarming at 23°C for 15 min, 30-jul aliquots were applied to sample wells. The tracking dye, 0.1% bromphenol blue (1.5 j1), was included in some samples. Gels were electrophoresed horizontally for 20 min at 50 V, 15 min at 100 V, and 4 h at 150 V. When the bromphenol blue dye reached the 0.3/ 2% gel interface, sample wells were filled with 0.3% agarose in running buffer to prevent loss of any material that may have remained in the wells. After electrophoresis, the gels were fixed in 10% acetic acid-25% isopropanol for at least 2 h, soaked in 10% acetic acid-2% glycerol for 1-2 h, and finally dried with hot air under a heat lamp. The gels were placed with XAR-5 X-Omat film (Eastman Kodak Co., Rochester, NY) in film cassettes containing Chronex Lighting Plus intensifying screens (E. I. du Pont de Nemours and Co., Inc., Wilmington, DE) for 4-7 d at -700C.
Association of Vi VIII:CAg and Ca2`-treated VIII:C protein with Ca2+-treated vWF. To prepare Ca2-treated vWF, 6.0 ml of normal citrated plasma containing I mM DFP and 100 U/ml Trasylol was gel filtered over a 2.5 X 30-cm column ofBio-Rad A5 M agarose equilibrated with VBS, 1 mg/ml BSA, 10 U/ml Trasylol, and 1 mM DFP. The V0 fractions from three columns were combined and mixed with human IgG, 1 mg/ml final concentration. The IgG, in a stock solution of 100 mg/ml VBS heated to 560C for 30 min before use, acted as a carrier protein to aid in precipitation.
Protein in the V0 fraction was precipitated with PEG-400, 38% final concentration, at 0°C for 1.5 h. After centrifuging the solution at 12,000 g for 10 min, the precipitate was dissolved in 2.0 ml/VBS, 0.2 mg/ml BSA, and 10 U/ml Trasylol. To separate V0 VIII:CAg from vWF, the dialyzed V0 solution was adjusted to 0.25 M CaCl2, incubated at 37°C for 1 h, and gel filtered on a 1.6 X 50-cm column of Fractogel TSK HW-75(F) (Pierce Chemical Co., Rockford, IL). The column was buffered in 1 mM benzamidine HCG, 0.01 mg/ml soybean trypsin inhibitor, 10 U/ml Trasylol, 0.2 mg/ml BSA, 0.25 M CaCI2, 0.02% sodium azide, and 0.05 M imidazole, pH 6.8. Column fractions were assayed for VIII:C activity and for vWF by immunoelectrophoresis. Those with vWF but no VIII:C were pooled, concentrated against Aquacide, and dialyzed against VBS containing 10 U/ml Trasylol-3 mM CaCl2. Eluate fractions containing Ca2+-dissociated VIII:C were similarly concentrated and dialyzed.
To determine if V5 VIII:CAg associates with vWF protein, Ca2+-treated vWF (0.25 ml, 0.44 U/ml) was incubated (370C, 2 h) with 0.25 ml V1 VIII:CAg (0.5 U/ml) in VBS containing 2 mM DFP, 48 U/ml hirudin, 180 U/ml Trasylol, 1 MM pAPMSF, and 3 mM CaC12. After an additional incubation with 0.25 ml '251-Fab (5 X 104 cpm) plus 2%
PEG-4000 at final concentration for 2 h at 37°C, the solution was gel filtered over a 0.9 X 47-cm A5 M column equilibrated with VBS, 0.2 mg/ml BSA, 0.5 mM DFP, and 3 mM CaCI2. Column fractions were examined for radioactivity and vWF protein. Control experiments included gel chromatography of '25I-Fab plus Ca2+-treated vWF.
The Ca2+-dissociated VIII:C protein was treated similarly to V, VIII:CAg to see if it would recombine with vWF. A 0.25-ml aliquot of Ca2+-dissociated VIII:C (0.5 U/ml VIII:CAg) was incubated with Ca2+-treated vWF (0.25 ml, 0.53 U/ml), incubated with '25I-Fab (5.5 X 104), and chromatographed over A5 M at 0.9 X 45 cm (see above). As a control, Ca2+-dissociated VIII:C plus '251-Fab was also gel filtered.
SDS-3% and 4% polyacrylamide-0.5% agarose gel electrophoresis (SDS-3% or 4% PAAGE). Slab gels were formed with a final concentration of either 3 The same fixing and autoradiographic development procedures were used as for the 0.3/2% agarose gels, except that the gels were dried in a 56°C oven for 6 h rather than under a heat lamp. Autoradiographic patterns were quantified by densitometry.
Thrombin treatment of VIII:CAg and analysis by electrophoretic procedures. The peak V0 eluate fractions (-I ml) of gel filtered plasma (see above) containing the highest level of VIII:C was used for thrombin digestion experiments. V0 samples were incubated with 100 KIU/ml Trasylol for 20 min at 23°C before thrombin addition.
Thrombin (sp act 2,500 U/mg, 0.05 U/ml final concentration), kindly provided by Dr. John Fenton II (New York State Department ofHealth, Albany, NY), was added at 23°C to an aliquot (0.75 ml) of the V0 fraction. At various time points, 25-,ul samples were withdrawn, diluted 20-fold, and assayed for VIII:C. At each time point two additional samples were withdrawn: 60 gl for immunoelectrophoresis and 0.3% agarose gels, and 25 tI for SDS-4% PAAGE. A sample (0.12 ml) of the V0 solution, untreated with thrombin, was set aside to be used for assays of the zero-time point. An additional aliquot (0.12 ml) ofthe V0 fraction was incubated either with 0.5 or I U/ml thrombin for 15 min, then assayed for VIII-related activities.
Before immunoelectrophoresis and electrophoresis on 0.3% agarose gels, the 60-Mil aliquots were treated with '25I-Fab solution containing inhibitors and PEG under the same conditions as samples prepared for 0.3/2% agarose electrophoresis.
Similarly, the 25-Ml aliquots for SDS-PAAGE were incubated with 27 Ml '25l-Fab solution containing inhibitors and PEG, but the samples were then incubated with an equal volume of SDS-urea denaturing buffer, and 30-Ml aliquots were analyzed by SDS-4% PAAGE.
The same thrombin activation and sampling procedures were used to examine DEAE-concentrated V1 VIII:CAg. The V, fraction, however, was rich in fibrinogen. 
Results
Two distinct VIII:CAg populations in normal plasma. Normal plasma was gel filtered on 6% agarose and fractions assayed for VIII:C, VIII:CAg, and vWF antigen (Fig. 1 A) . Almost all vWF antigen was present in the V0 peak, while VIII:CAg was present both in the V0 peak and in a V1 position near that of fibrinogen. The Vi VIII:CAg comprised 15% ofthe total recovered VIII:CAg measured by fluid-phase immunoradiometric assay.
VIII;C activity in the V0 region was approximately twice that predicted from the VIII:CAg level. This may reflect VIII:C activation during chromatography or a difference in the precipitating properties of VIII:CAg present in the V0 region vs. that in whole plasma used to prepare the standard curve for VIII:CAg determination. No VIII:C activity was observed in the V1 eluate fractions. This was true even when eluate fractions containing 0.01-0.03 U/ml VIII:CAg (levels corresponding to the lower limits of VIII:C activity detectable in whole plasma)
were concentrated to as much as 0.6 U/ml VIII:CAg.
Although immunoreactive material was present at the Vi position, the absence of VIII:C activity raised the possibility that the antigen might not be related to VIII:C. This could occur if '251-Fab, used to detect VIII:CAg, was nonspecific.
To provide a functional correlation of the V1 antigenic material with VIII:C, inhibitor blocking experiments were performed (16) based on the ability of Fab to neutralize VIII:C activity (Table I) normal plasma, or added to normal plasma just before the reagents were mixed with hemophilic plasma plus calcium, clotting times were unaffected (see also Electrophoretic separation ofVO and V1 VIII:CAg on agarose gels.In a more analytically useful procedure to detect V0 and V1 VIII:CAg in whole plasma, '251I-Fab-treated plasma was electrophoresed into 0.3/2% agarose gels without SDS (Fig. 2) No evidence of V1 VIII:CAg binding to vWF after gelfiltration.Vi VlII:CAg eluate (0.1 U/ml VIII:CAg, I vol) was incubated for 2 h at 370C with citrated hemophilic plasma (1 vol) containing <3% VIII:CAg and <1% VIII:C, in order to determine if Vi VIII:CAg would bind to vWF protein (120% vWF antigen).
All V, VIII:CAg remained at the V1 position both by gel filtration chromatography and by 0.3/2% agarose gel electrophoresis, indicating that persistent VIII:CAg-vWF complexes had not formed. These conditions are similar to those used by others (19) to show that calcium-dissociated VIII:C protein obtained from the V0 fraction could rebind to vWF.
Since vWF in hemophilic plasma might lack the binding site for VIII:CAg, vWF from a normal individual was treated with 0.25 M CaCl2 to dissociate VIII:C and VIII:CAg. The Ca2+_ treated vWF was then incubated with Vi VIII:CAg (Fig. 3 A) at 37°C with 3 mM CaCl2 and proteolytic inhibitors, followed by incubation with 1251-Fab and gel filtration. A low concentration of CaCl2 (3 mM) was included in these experiments because the binding of Ca2+-dissociated VIII:C to Ca2+-treated vWF and hemophilic vWF increases compared with gel filtration without calcium (20) . The trace increase of radioactivity in the V0 shows that virtually no Vi VIII:CAg bound to vWF.
As a control, Ca2+-dissociated VIII:C protein, obtained by gel filtration of VIII:C/vWF in 0.25 M CaCl2, was similarily incubated with Ca2+-treated vWF and '251I-Fab, and gel filtered.
In contrast with Vi VIII:CAg, there was a significant increase in Ca2+-dissociated VIII:CAg eluting in the V0 with vWF (Fig.  3 B) .
Characterization of Vo and Vi VIII:CAg by SDS-PAAGE.
To obtain apparent molecular weights of VIII:CAg dissociated from vWF, samples containing VIII:CAg were compared on SDS polyacrylamide agarose gels. After incubation with 12511 Fab, samples were electrophoresed and '251I-Fab-VIII:CAg complexes were detected by autoradiography. Apparent molecular weights reported here are those ofthe free VIII:CAg, rather than the antigen-antibody complex, and were calculated by subtracting the 5 X 104 apparent mol wt of 1251I-Fab from that of the complex (8, 9) . Molecular weight values are those determined from electrophoresis on 4% polyacrylamide-0.5% agarose gels (4% PAAGE). These gels gave better resolution ofprotein bands and apparent mol wt values 10-15 X 103 lower than those obtained with 3% polyacrylamide-0.5% agarose gels (8, 18) used previously.
The major VIII:CAg form in whole plasma was of mol wt 2.4 X 105 with other antigenic forms comprising -30% of the total by densitometry (Fig. 4) . The 2.4 X 105-mol wt VIII:CAg form was also predominant in both VO and V1 gel filtration fractions.
VIII:CAg in the VO region was extremely susceptible to a process, most likely proteolysis, resulting in a lower molecular weight VIII:CAg form (Fig. 4) . Gel filtration performed with (column 1) or without (column 2) careful preequilibration (Fig.  4) Effect ofthrombin on VO and Vi VIII:CAg examined by SDS-4% PAAGE. Thrombin-treated VO and V1 VIII:CAg were examined on SDS-4% PAAGE to detect molecular weight changes that might correspond to the appearance and inactivation of VIII:C activity.
Within 1 min after thrombin addition (0.05 U/ml final concentration) to VO, the I X 105-mol wt VIII:CAg form became predominant, with concomitant loss of higher molecular weight antigens (Fig. 5) . The I X 105-mol wt species slowly declined over 9 min at a rate proportional to the development of a broad major band, mol wt 0.8 X 105, and a minor band, mol wt 0.4 X IO'. After 15 min incubation with either 0.5 or I U/ml thrombin, most material was of mol wt 0.8 X 105. The width of the 0.8 X 105-mol wt band suggests that several antigenic forms of similar size were present. The rise and fall of thrombin-generated VIII:C activity could be best fitted to the appearance and disappearance of the I X 105-mol wt band (Fig. 5 B) . However, the correspondence was not exact. At peak VIII:C activity (3 min), both the I-and 0.8 X 105-mol wt bands were present in approximately equal proportions. Sampling at closer (2 min) time intervals gave the same result.
Thrombin activation experiments were also performed on column eluate fractions containing V1 VIII:CAg (0.07 U/ml VIII:CAg, 0.1 U/ml thrombin). The gel pattern was similar to that of Vo VIII:CAg with a loss of the 2.4 X 105-mol wt band and formation ofthe 1-and 0.8 X 105-mol wt bands. Low levels of VIII:C activity were generated from an undetectable amount before thrombin addition to a peak of 0.04 VIII:C U/ml at 1 min, and 0.01 VIII:C U/ml after 9 min. Association of thrombin-activated VO VIII:CAg with vWF.
To determine the relationship among thrombin-activated forms of VIII:CAg and vWF, V0 samples used above in the SDS-4% PAAGE experiments were examined by one-dimensional immunoelectrophoresis in a nondenaturing system (Fig. 6 ). (Fig. 7) . After 1 min of exposure to 0.1 U/ml thrombin, at peak VIII:C activity when most VIII:CAg was in the 1-and 0.8 X 105-mol wt forms, VIII:CAg was detected at position 1 and at the more cathodic position 2. When most VIII:CAg was of mol wt 0.8 X 10, after 15 min of exposure to 1 U/ml thrombin, '25I-Fab-VIII:CAg migrated to position 2 and to the more anodic position 3. These data, along with the gel filtration studies, suggest that the 2. (8, 19, 24, 25) . The latter binds to hemophilic and Ca2--treated vWF and has VIII:C activity without thrombin activation. While both V, VIII:CAg and Ca2+-dissociated VIII:C have approximately the same molecular weight, 2-3 X iOs mol wt under nondenaturing conditions (1, 2, 4, 5), Ca2+-dissociated VIII:C is primarily of mol wt 1 X 105 on SDS-PAGE and PAAGE (4, 8, 24, 25) . This suggests that Vi VIII:CAg protein is held together by covalent bonds not present in the calcium-treated material. It is not clear at present whether improvements in the purification of Ca2+-dissociated VIII:C protein, as by inclusion of large amounts of proteolytic inhibitors in all stages of preparation, will yield a major protein species with molecular weight characteristics of V1 VIII:CAg.
The finding that V0 VIII:CAg binds to vWF, while Vi VIII:CAg is unbound, has implications for the design of quantitative assays for VIII:CAg. Solid-phase immunoradiometric assays, which include reaction oftest samples with heterologous anti-vWF protein (26) to quantify VIII:C, will not allow the detection of V1 VIII:CAg. In addition, there are differences in the solubility of the two antigen forms that affect the quantitative fluid-phase assay. Ammonium sulfate (38% saturation) used in fluid-phase immunoradiometric assay (13) was less effective than 38% PEG-400 in precipitating '25I-Fab-V; VIII:CAg (Weinstein, M., unpublished observations).
We found no single antigenic form whose appearance and disappearance correlated exactly with the thrombin-induced rise and fall in VIII:C activity. Although VIII:C activity increased simultaneously with the generation of the 1 X 105-mol wt VIII:CAg fragment, peak activity was reached only when equal amounts of 1 X lO and 8 X 104 VIII:CAg were present. When the multiple VIII:CAg forms comprising the broad band with mol wt of 8 X 104 were predominant, however, no VIII:C activity was detectable.
It has been suggested that VIII:C activity is fully expressed only when thrombin is in a complex with proteolyzed VIII:CAg (27, 28) . The observed level of VIII:C activity might result from the combined rates of VIII:CAg activation, proteolytic or conformational (28) inactivation, and relatively slow thrombin-VIII:CAg complex formation.
Alternatively, some active forms of the VIII:C protein may not be detected by the SDS-PAAGE gel method. In the intact 2.4 X 105-mol wt form of VIII:CAg, '251-Fab blocks the ability of VIII:CAg to act as a cofactor. But upon activation, the peptide fragment containing the cofactor site might become separated from the antigenic site and thus not be visible by our gel procedures. There is evidence for the appearance of several nonimmunogenic fragments of purified VIII:C upon thrombin activation (8) , but the correlation ofone or more ofthese fragments with VIII:C activity is still speculative (29) .
Similarly, molecular weight alteration, too small to be seen by SDS-PAAGE, could yield major changes in the physical properties of VIII:CAg. For example, V0 VIII:CAg treated with 1 U of thrombin for 15 min produced a major antigenic form with mol wt 8 X 104 on SDS-PAAGE, but produced two antigenic forms of widely different electrophoretic mobility on one-dimensional agarose gel electrophoresis (Fig. 7) .
V0 VIII:CAg association with vWF and changes induced by thrombin can be summarized as follows: The 2.4 X 105-mol wt V0 VIII:CAg form was initially bound to vWF; treatment with thrombin quickly produced VIII:CAg of -1 X 105 mol wt, a major portion of which was still associated with vWF accompanied by greater VIII:C activity; more prolonged digestion yielded inactive 0.8 X 10 mol wt VIII:CAg no longer bound to vWF. The reduced association ofthe latter two antigen forms with vWF, compared with the 2.4 X 105-mol wt V0 VIII:CAg, is in agreement with the observation of Davies et al. (30) on VIII:CAg binding to thrombin-treated vWF. As with V1 VIII:CAg, this reduced binding of antigen to vWF could affect quantitative assays for VIII:C proteins and could be responsible for the commonly observed apparent reduction in VIII:CAg after thrombin treatment of plasma (31).
Vi VIII:CAg undergoes the same reaction sequence with thrombin as V0 VIII:CAg to yield VIII:C activity. While the role of V1 VIII:CAg in in vivo coagulation remains to be elucidated, it is a form of Factor VIII that does not depend on nonphysiological ionic strength conditions to act independently of vWF.
